Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2 Study of Rituxan Hycela in Patients With Advanced Melanoma Undergoing Combination Immune Checkpoint Blockade With Nivolumab and Ipilimumab

NCT03719131 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT03719131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03719131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2 Study of Rituxan Hycela in Patients With Advanced Melanoma Undergoing Combination Immune Checkpoint Blockade With Nivolumab and Ipilimumab
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Completed
Start date
June 5, 2019
Completion date
April 9, 2025
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous melanoma, stage iii, cutaneous melanoma, stage iv, stage iii melanoma, stage iiia skin melanoma, stage iiib skin melanoma, stage iiic skin melanoma, stage iv skin melanoma, unresectable melanoma